PTC Therapeutics
Coordinates: 40°33′03″N 74°25′23″W / 40.550722°N 74.423071°W
| Public | |
| Traded as | NASDAQ: PTCT |
| Industry | Pharmaceuticals |
| Headquarters | South Plainfield, New Jersey, United States |
| Website |
ptcbio |
PTC Therapeutics is a US pharmaceutical company focused on the development of small molecule, orally administered treatments for orphan diseases.[1]
Since 2003, PTC has been working on a drug for Duchenne muscular dystrophy.[2]
In September 2009, PTC has entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases.[3]
As of May 2016, PTC portfolio includes small-molecule compounds for treatment of spinal muscular atrophy (RG7800 and RG7916) and Duchenne muscular dystrophy (Ataluren and another exon skipping compound).[4]
References
- ↑ Bhutta, Sunya (December 2013). "Biopharma Blossoming in the Garden State". Biobusiness. Gen. Eng. Biotechnol. News. 33 (21). p. 15.
- ↑ Hamed SA (2006). "Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy". IDrugs : the investigational drugs journal. 9 (11): 783–9. PMID 17096300.
- ↑ Bratulic, Anna (2009-09-02). "Roche, PTC Therapeutics to partner on CNS drug discovery - FirstWord Pharma". Firstwordplus.com. Retrieved 2016-05-14.
- ↑ "PTC Therapeutics | Pipeline". Ptcbio.com. Retrieved 2016-05-14.
Further reading
- Schneider, Ilene (2009). "Firm Aims to Regulate RNA in Rare Diseases". Genetic Engineering & Biotechnology News. 29 (8): 14. Retrieved 2009-04-25.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.